Mathematics in the realm of lapatinib: 500 + 500 = 1,500?

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 2940-2942

  Seruga, Bostjan ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; BREAST TUMOR; DRUG ADMINISTRATION; ENZYMOLOGY; FEMALE; GENETICS; NOTE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 46449088817     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.5282     Document Type: Editorial

References (20)

1. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-796, 2007
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
3. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007
4. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
5. Graus-Porta D, Beerli RR, Daly JM, et al: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655, 1997
6. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
7. Gomez HL, Doval DC, Chavez MA, et al: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999-3005, 2008
8. Clark KJ, Keith BR, Alligood K, et al: Pharmacokinetics and pharmacodynamics of GW572016 following oral administration to female BT474-bearing CB-17SCID mice. 2002 Annual Meeting of the American Association of Pharmaceutical Scientists, Toronto, Canada, November 11-14, 2002 (abstr W5286)
9. Koch KM, Lee D, Jones S, et al: Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients. Eur J Cancer 1:S169, 2003 (suppl)
10. Baselga J, Carbonell X, Castaneda-Soto NJ, et al: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162-2171, 2005
11. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
12. Burris HA 3rd, Hurwitz HI, Dees EC, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313, 2005
13. Pandite L, Burris HA, Jones S, et al: A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol 22:238s, 2004 (suppl; abstr 3179)
14. Chu QS, Schwartz G, de Bono J, et al: Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol 25:3753-3758, 2007
15. Blackwell KL, Kaplan EH, Franco SX, et al: A phase II, open label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 22:196s, 2004 (suppl; abstr 3006)
16. Burstein HJ, Storniolo AM, Franco S, et al: A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol [epub ahead of print on February 17, 2008]
17. Smylie M, Blumenschein GR, Dowlati A, et al: A phase II multicenter trial comparing two schedules of lapatinib as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 25:412s, 2007 (suppl; abstr 7611)
18. GlaxoSmithKline: TYKERB label. http://us.gsk.com/products/assets/ us_tykerb.pdf
19. Ratain MJ, Cohen EE: The value meal: How to save $1,700 per month or more on lapatinib. J Clin Oncol 25:3397-3398, 2007
20. Reddy N, Cohen R, Whitehead B, et al: A phase I, open-label, three-period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmacol Ther 81:S16-S17, 2007 (suppl)